Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B

Trial Profile

A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABI-H0731 (Primary) ; Entecavir; Peginterferon alfa-2a; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Assembly Biosciences
  • Most Recent Events

    • 13 Nov 2018 Final results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
    • 12 Nov 2018 Results published in an Assembly Biosciences media release.
    • 12 Nov 2018 According to an Assembly Biosciences media release, final data from phase Ib portion was presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top